Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value.
Adult
Aged
Cell Proliferation
Colorectal Neoplasms
/ pathology
Female
Histocytochemistry
Humans
Liver
/ pathology
Liver Neoplasms
/ pathology
Male
Melanoma
/ pathology
Middle Aged
Neoplasms, Second Primary
/ pathology
Prognosis
Skin Neoplasms
/ pathology
Uveal Neoplasms
/ pathology
Young Adult
Melanoma, Cutaneous Malignant
angiotropism
cutaneous melanoma
desmoplastic
extravascular migratory metastasis
histopathological growth patterns
liver
metastasis
pericytic mimicry
replacement
vascular co-option
Journal
The journal of pathology. Clinical research
ISSN: 2056-4538
Titre abrégé: J Pathol Clin Res
Pays: England
ID NLM: 101658534
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
19
12
2019
revised:
10
02
2020
accepted:
14
02
2020
pubmed:
19
4
2020
medline:
2
7
2021
entrez:
19
4
2020
Statut:
ppublish
Résumé
Among visceral metastatic sites, cutaneous melanoma (CM) metastasises initially to the liver in ~14-20% of cases. Liver metastases in CM patients are associated with both poor prognosis and poor response to immunotherapy. Histopathological growth patterns (HGPs) of liver metastases of the replacement and desmoplastic type, particularly from colorectal cancer and uveal melanoma (UM), may impart valuable biological and prognostic information. Here, we have studied HGP in 43 CM liver metastases resected from 42 CM patients along with other prognostic factors from three institutions. The HGPs (replacement, desmoplastic, pushing) were scored at the metastasis-liver interface with two algorithms: (1) 100% desmoplastic growth pattern (dHGP) and any (≥1%) replacement pattern (any-rHGP) and (2) >50% dHGP, >50% rHGP or mixed (<50% dHGP and/or rHGP, pushing HGP). For 1 patient with 2 metastases, an average was taken to obtain 1 final HGP yielding 42 observations from 42 patients. 22 cases (52%) had 100% dHGP whereas 20 (48%) had any replacement. Cases with rHGP demonstrated vascular co-option/angiotropism. With the development of liver metastasis, only rHGP (both algorithms), male gender and positive resection margins predicted diminished overall survival (p = 0.00099 and p = 0.0015; p = 0.034 and p = 0.024 respectively). On multivariate analysis, only HGP remained significant. 7 of 42 (17%) patients were alive with disease and 21 (50%) died with follow-up after liver metastases ranging from 1.8 to 42.2 months (mean: 20.4 months, median: 19.0 months). 14 (33%) patients with previously-treated metastatic disease had no evidence of disease at last follow up. In conclusion, we report for the first time replacement and desmoplastic HGPs in CM liver metastases and their prognostic value, as in UM and other solid cancers. Of particular importance, any rHGP significantly predicted diminished overall survival while 100% dHGP correlated with increased survival. These results contribute to a better understanding of the biology of CM liver metastases and potentially may be utilised in managing patients with these metastases.
Identifiants
pubmed: 32304183
doi: 10.1002/cjp2.161
pmc: PMC7339161
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
195-206Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2020 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd.
Références
Gastroenterol Hepatol Bed Bench. 2012 Spring;5(2):79-83
pubmed: 24834204
Science. 2001 Oct 19;294(5542):559-63
pubmed: 11577199
Nature. 2014 Mar 6;507(7490):109-13
pubmed: 24572365
Melanoma Res. 2017 Apr;27(2):134-139
pubmed: 28099368
Sci Rep. 2016 Apr 06;6:23834
pubmed: 27048955
Br J Surg. 2013 Aug;100(9):1138-47
pubmed: 23775340
Mod Pathol. 2014 Dec;27(12):1641-8
pubmed: 24851832
Nat Med. 2016 Nov;22(11):1294-1302
pubmed: 27748747
Lab Invest. 2017 Feb 27;:
pubmed: 28240745
Cancer. 2014 Mar 15;120(6):781-9
pubmed: 24301420
Development. 2015 Jun 15;142(12):2094-108
pubmed: 26081571
Angiogenesis. 2020 Feb;23(1):27-41
pubmed: 31720876
Angiogenesis. 2019 May;22(2):355-368
pubmed: 30637550
Ann Surg Oncol. 2006 May;13(5):712-20
pubmed: 16538410
Nat Rev Clin Oncol. 2019 Aug;16(8):469-493
pubmed: 30816337
Br J Cancer. 2017 Nov 7;117(10):1427-1441
pubmed: 28982110
Ann Surg Oncol. 2019 Dec;26(13):4587-4598
pubmed: 31605342
Am J Surg Pathol. 2008 Sep;32(9):1396-403
pubmed: 18670348
Actas Dermosifiliogr. 2013 Sep;104(7):593-7
pubmed: 23876678
J Cutan Pathol. 2019 Jul;46(7):498-507
pubmed: 30903664
Pigment Cell Melanoma Res. 2013 Sep;26(5):746-54
pubmed: 23789776
Angiogenesis. 2020 Feb;23(1):43-54
pubmed: 31655928
J Pathol Clin Res. 2018 Oct;4(4):227-240
pubmed: 29917326
Jpn J Clin Oncol. 1996 Feb;26(1):24-9
pubmed: 8551663
Cancer Res. 2015 Dec 1;75(23):5014-22
pubmed: 26354021
Histopathology. 2012 Nov;61(5):889-98
pubmed: 22716270